Actinic Keratoses Clinical Trial
Official title:
A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses
The purpose of this study is to determine if use of topical imiquimod cream after cryotherapy of actinic keratoses reduces the total number of lesions (those treated with cryotherapy and new ones) at follow-up.
Actinic keratoses are common skin lesions associated with excess sun exposure. Over time,
there is a small risk a lesion may progress to skin cancer. Since one can not predict which
actinic keratosis will progress, the standard of care is to treat the lesions. The most
commonly used method to treat actinic keratoses in the United States is with cryotherapy,
which uses intense cold to freeze and destroy the lesions. Efficacy appears to be related to
how long one freezes the lesion, but increasing the freeze time may result in increased pain
and/or skin pigment changes after treatment.
Cryotherapy is a provider-administered "focal" treatment that only treats the lesions that
are frozen. There may be early actinic keratoses in the skin surrounding treated lesions
that are not easily seen; these may progress over time to visible lesions. There several
patient-administered topical treatments for actinic keratoses that are applied to a
treatment area or "field" rather than to specific lesions. Imiquimod 5% cream is one such
treatment, and is approved in the United States for the treatment of AKs with a dosing
regimen of 1 packet applied 2 times per week to a 25 cm2 area 2x/week for 16 weeks.
The study will use a split-face design (one side of face treated and the other side
untreated) to explore whether a 4-week course of topical imiquimod 5% cream after
cryotherapy of actinic keratoses reduces the total number of lesions (those treated with
cryotherapy and new ones) in the treatment area at follow-up.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03575780 -
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
|
Phase 1 | |
| Completed |
NCT04085367 -
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
|
Phase 3 | |
| Recruiting |
NCT05937529 -
Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
|
N/A | |
| Completed |
NCT02520700 -
A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses
|
N/A | |
| Terminated |
NCT01538901 -
Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01354717 -
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
|
Phase 3 | |
| Completed |
NCT00742391 -
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
|
Phase 3 | |
| Completed |
NCT03285477 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
|
Phase 3 | |
| Suspended |
NCT03963102 -
Duration of Ameluz Application in Acral Actinic Keratoses Response
|
Phase 4 | |
| Not yet recruiting |
NCT06026358 -
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
|
Phase 4 | |
| Completed |
NCT02622594 -
Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times
|
Phase 4 | |
| Completed |
NCT00786994 -
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
|
Phase 2 | |
| Completed |
NCT00544258 -
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
|
Phase 1 | |
| Completed |
NCT04024579 -
Treatment of Actinic Keratosis With 5% KOH Solution
|
||
| Completed |
NCT04843553 -
Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
|
Early Phase 1 | |
| Completed |
NCT03315286 -
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
|
N/A | |
| Completed |
NCT03279328 -
Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
|
Phase 4 | |
| Completed |
NCT02062853 -
Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video
|
N/A | |
| Terminated |
NCT01532453 -
Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients
|
Phase 3 | |
| Active, not recruiting |
NCT00829192 -
Phase II AK Study in Organ Transplant Patients
|
Phase 2 |